Literature DB >> 24107802

Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.

R J Motzer1, T Johnson, T K Choueiri, K C Deen, Z Xue, L N Pandite, C Carpenter, C F Xu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24107802      PMCID： PMC6394110          DOI： 10.1093/annonc/mdt394

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

Review 1.  Pazopanib: a Review in Advanced Renal Cell Carcinoma.

Authors:  James E Frampton
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Authors:  Meta H Diekstra; Xiaoyan Liu; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Pharmacogenomics       Date:  2016-12-14       Impact factor: 2.533

Review 3.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

4.  Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Authors:  Meta H M Diekstra; Jesse J Swen; Loes F M van der Zanden; Sita H Vermeulen; Epie Boven; Ron H J Mathijssen; Koya Fukunaga; Taisei Mushiroda; Fumiya Hongo; Egbert Oosterwijk; Anne Cambon-Thomsen; Daniel Castellano; Achim Fritsch; Jesus Garcia Donas; Cristina Rodriguez-Antona; Rob Ruijtenbeek; Marius T Radu; Tim Eisen; Kerstin Junker; Max Roessler; Ulrich Jaehde; Tsuneharu Miki; Stefan Böhringer; Michiaki Kubo; Lambertus A L M Kiemeney; Henk-Jan Guchelaar
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

Review 5.  PharmGKB summary: pazopanib pathway, pharmacokinetics.

Authors:  Caroline F Thorn; Manish R Sharma; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

6.  Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.

Authors:  Daniel L Hertz; Lisa M McShane; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2022-03-24       Impact factor: 50.717

7.  A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

Authors:  Véronique Diéras; Thomas Bachelot; Mario Campone; Nicolas Isambert; Florence Joly; Christophe Le Tourneau; Philippe Cassier; Emmanuelle Bompas; Pierre Fumoleau; Sabine Noal; Christine Orsini; Marta Jimenez; Diane Charlotte Imbs; Etienne Chatelut
Journal:  Oncol Ther       Date:  2016-08-18

8.  Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.

Authors:  Parul Patel; Zhengyu Xue; Karen S King; Laura Parham; Susan Ford; Yu Lou; Kalpana K Bakshi; Kenneth Sutton; David Margolis; Arlene R Hughes; William R Spreen
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

Review 9.  Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.

Authors:  Hana Studentova; Jindriska Volakova; Martina Spisarova; Anezka Zemankova; Kvetoslava Aiglova; Tomas Szotkowski; Bohuslav Melichar
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067

Review 10.  UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.

Authors:  Ryan S Nelson; Nathan D Seligson; Sal Bottiglieri; Estrella Carballido; Alex Del Cueto; Iman Imanirad; Richard Levine; Alexander S Parker; Sandra M Swain; Emma M Tillman; J Kevin Hicks
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.